Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

The Somatic Genomic Landscape Of Glioblastoma

C. Brennan, Roel G. W. Verhaak, A. McKenna, B. Campos, H. Noushmehr, S. Salama, Siyuan Zheng, Debyani Chakravarty, J. Z. Sanborn, S. Berman, R. Beroukhim, Brady Bernard, C. Wu, G. Genovese, I. Shmulevich, Jill Barnholtz‐Sloan, Lihua Zou, Rahulsimham Vegesna, Sachet A. Shukla, Giovanni Ciriello, W. Yung, W. Zhang, C. Sougnez, T. Mikkelsen, K. Aldape, D. Bigner, E. Meir, M. Prados, Andrew Sloan, K. Black, J. Eschbacher, G. Finocchiaro, W. Friedman, D. Andrews, A. Guha, M. Iacocca, B. O'Neill, G. Foltz, J. Myers, D. Weisenberger, R. Penny, R. Kucherlapati, C. Perou, D. Hayes, R. Gibbs, M. Marra, G. B. Mills, E. Lander, P. Spellman, R. Wilson, Chris Sander, J. Weinstein, M. Meyerson, S. Gabriel, P. Laird, D. Haussler, G. Getz, L. Chin
Published 2013 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
We describe the landscape of somatic genomic alterations based on multidimensional and comprehensive characterization of more than 500 glioblastoma tumors (GBMs). We identify several novel mutated genes as well as complex rearrangements of signature receptors, including EGFR and PDGFRA. TERT promoter mutations are shown to correlate with elevated mRNA expression, supporting a role in telomerase reactivation. Correlative analyses confirm that the survival advantage of the proneural subtype is conferred by the G-CIMP phenotype, and MGMT DNA methylation may be a predictive biomarker for treatment response only in classical subtype GBM. Integrative analysis of genomic and proteomic profiles challenges the notion of therapeutic inhibition of a pathway as an alternative to inhibition of the target itself. These data will facilitate the discovery of therapeutic and diagnostic target candidates, the validation of research and clinical observations and the generation of unanticipated hypotheses that can advance our molecular understanding of this lethal cancer.
This paper references
Genes Dev
10.1101/gad.189001.112
STAR RNA-binding protein Quaking suppresses cancer via stabilization of specific miRNA.
A. Chen (2012)
10.1038/nature11412
Comprehensive molecular portraits of human breast tumors
D. Koboldt (2012)
10.1038/nbt.2203
Absolute quantification of somatic DNA alterations in human cancer
S. Carter (2012)
10.1038/nature12213
Mutational heterogeneity in cancer and the search for new cancer genes
M. Lawrence (2013)
10.1186/gb-2011-12-4-r41
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers
Craig H. Mermel (2011)
10.1038/ng.238
Integrated detection and population-genetic analysis of SNPs and copy number variation
S. McCarroll (2008)
10.1038/nature08822
The landscape of somatic copy-number alteration across human cancers
R. Beroukhim (2010)
10.1016/j.cell.2012.08.029
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
M. Imielinski (2012)
10.1016/j.ccr.2010.03.017
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.
H. Noushmehr (2010)
10.1093/HMG/4.4.541
Isolation and characterization of a novel gene deleted in DiGeorge syndrome.
H. Kurahashi (1995)
10.1093/nar/gkm995
The microRNA.org resource: targets and expression
Doron Betel (2008)
10.1016/J.MOLCEL.2007.06.017
MicroRNA targeting specificity in mammals: determinants beyond seed pairing.
A. Grimson (2007)
10.1016/S0303-7207(06)00207-3
Acknowledgments
(2006)
10.1093/neuonc/noq190
DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression.
S. Zheng (2011)
10.1093/neuonc/nou223
CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.
Q. Ostrom (2014)
10.1016/J.CCR.2006.02.019
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.
H. Phillips (2006)
A complete description of the EGF-receptor exon structure: implication in oncogenic activation and domain evolution.
T. Callaghan (1993)
10.1101/gad.187922.112
Emerging insights into the molecular and cellular basis of glioblastoma.
Gavin P Dunn (2012)
Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations.
T. Shono (2001)
10.1101/gad.1890510
Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma.
María-del-Mar Inda (2010)
PLoS Genet
10.1056/NEJMoa1008433
ARID1A mutations in endometriosis-associated ovarian carcinomas.
Kimberly C. Wiegand (2010)
10.1016/j.cell.2004.12.035
Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets
B. P. Lewis (2005)
10.18632/ONCOTARGET.689
Whole exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma
K. Kannan (2012)
10.1038/nsmb.1533
miR-29 miRNAs activate p53 by targeting p85α and CDC42
S. Park (2009)
10.1016/j.ccr.2008.02.010
Feedback Circuit among INK4 Tumor Suppressors Constrains Human Glioblastoma Development
R. Wiedemeyer (2008)
10.1126/science.1220834
Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
Devendra Singh (2012)
10.1016/J.SEMCANCER.2006.10.007
Formation of non-random extrachromosomal elements during development, differentiation and oncogenesis.
F. Kuttler (2007)
10.1158/0008-5472.CAN-13-0186
Double minute chromosomes in glioblastoma multiforme are revealed by precise reconstruction of oncogenic amplicons.
J. Sanborn (2013)
476 Cell 155 , 462 – 477 , October 10 , 2013 a 2013 Elsevier Inc . Melanoma genome sequencing reveals frequent PREX 2 mutations
M. F. Berger (2012)
10.1038/nmeth.1363
BreakDancer: An algorithm for high resolution mapping of genomic structural variation
Ken Chen (2009)
10.1038/ng1910
Natural selection on human microRNA binding sites inferred from SNP data
K. Chen (2006)
10.1186/gb-2011-12-1-r1
A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries
Sheila A. Fisher (2010)
10.1073/pnas.1303607110
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal
P. Killela (2013)
10.2353/AJPATH.2007.070011
Genetic pathways to primary and secondary glioblastoma.
H. Ohgaki (2007)
10.1073/pnas.1120375109
Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-κB network
K. Holmes (2012)
10.1101/gr.082701.108
Most mammalian mRNAs are conserved targets of microRNAs.
Robin C Friedman (2009)
10.1038/nature10166
Integrated Genomic Analyses of Ovarian Carcinoma
D. Bell (2011)
10.1111/J.2517-6161.1995.TB02031.X
Controlling the false discovery rate: a practical and powerful approach to multiple testing
Y. Benjamini (1995)
10.1038/ng.806
A framework for variation discovery and genotyping using next-generation DNA sequencing data
M.A. DePristo (2011)
10.1038/ng1536
Combinatorial microRNA target predictions
Azra Krek (2005)
10.1016/j.cell.2011.09.029
Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs
Yvonne Tay (2011)
10.1371/journal.pone.0007752
Glioblastoma Subclasses Can Be Defined by Activity among Signal Transduction Pathways and Associated Genomic Alterations
C. Brennan (2009)
10.1038/nature09837
Initial genome sequencing and analysis of multiple myeloma
M. A. Chapman (2011)
10.1056/NEJMOA043331
MGMT gene silencing and benefit from temozolomide in glioblastoma.
M. Hegi (2005)
10.1158/2159-8290.CD-11-0284
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.
I. Vivanco (2012)
10.1016/J.YPAT.2012.10.013
Comprehensive molecular portraits of human breast tumours
A. McCullough (2013)
10.1093/neuonc/nos218
CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.
T. A. Dolecek (2012)
miR-29miRNAs activate p53 by targeting p85 alpha and CDC42
S. Y. Park (2009)
10.1056/NEJMoa1109016
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia.
L. Wang (2011)
10.1007/s00401-012-1031-3
Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations
Xiao-Yang Liu (2012)
10.1215/15228517-2009-025
IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.
K. Ichimura (2009)
10.1073/pnas.1114033109
Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response
N. Szerlip (2012)
10.1038/nature11404
Comprehensive genomic characterization of squamous cell lung cancers
P. Hammerman (2012)
10.1038/nature09639
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma
Ignacio Varela (2011)
IDH1mutations are present in themajority of common adult gliomas but rare in primary glioblastomas. Neuro-oncol
K. Ichimura (2009)
10.1038/ng.936
Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion
A. Bass (2011)
10.1016/j.cell.2011.09.041
An Extensive MicroRNA-Mediated Network of RNA-RNA Interactions Regulates Established Oncogenic Pathways in Glioblastoma
Pavel Sumazin (2011)
10.1056/NEJMoa1103782
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
P. Chapman (2011)
10.1038/nature11252
Comprehensive Molecular Characterization of Human Colon and Rectal Cancer
D. M. Muzny (2012)
10.1101/gr.125567.111
Mutual exclusivity analysis identifies oncogenic network modules.
Giovanni Ciriello (2012)
10.1101/gad.1972310
PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas.
T. Ozawa (2010)
10.1093/nar/gks1443
Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation
M. Costello (2013)
10.1093/NEUONC/NOU206.18
TERT PROMOTER MUTATIONS OCCUR FREQUENTLY IN GLIOMAS AND A SUBSET OF TUMORS DERIVED FROM CELLS WITH LOW RATES OF SELF-RENEWAL
H. Yan (2014)
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA , IDH 1 , EGFR , and NF 1 Citation Verhaak
Roel G. W. Verhaak (2010)
10.1038/nature07385
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
R. McLendon (2008)
10.1038/nature11071
Melanoma genome sequencing reveals frequent PREX2 mutations
M. Berger (2012)
10.1016/j.cell.2012.06.024
A Landscape of Driver Mutations in Melanoma
Eran Hodis (2012)
10.1101/gad.213686.113
A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival.
S. Zheng (2013)
10.1158/0008-5472.CAN-11-0821
Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.
Jeonghee Cho (2011)
Insulin-like growth factorbinding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-kB network
K M Holmes (2012)
10.1007/s00401-012-1016-2
MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status
P. Bady (2012)
10.1038/modpathol.2009.132
Comparative analysis of annexin-1 in neuroepithelial tumors shows altered expression with the grade of malignancy but is not associated with survival
J. Schittenhelm (2009)
10.1371/journal.pgen.1002772
Loss of ATRX, Genome Instability, and an Altered DNA Damage Response Are Hallmarks of the Alternative Lengthening of Telomeres Pathway
C. A. Lovejoy (2012)
10.1016/j.ccr.2012.08.024
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.
D. Sturm (2012)
10.1038/nature10833
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
J. Schwartzentruber (2012)
10.1016/S0092-8674(04)00045-5
MicroRNAs Genomics, Biogenesis, Mechanism, and Function
D. Bartel (2004)
miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42
S Y Park (2009)
10.1038/ng.237
Integrated genotype calling and association analysis of SNPs, common copy number polymorphisms and rare CNVs
J. Korn (2008)
10.1126/SCIENCE.1138764
Comment on "The Consensus Coding Sequences of Human Breast and Colorectal Cancers"
G. Getz (2007)
10.1093/bioinformatics/btl646
A faster circular binary segmentation algorithm for the analysis of array CGH data
E. S. Venkatraman (2007)
10.1126/science.1208130
The Mutational Landscape of Head and Neck Squamous Cell Carcinoma
Nicolas Stransky (2011)
10.1016/j.ccr.2011.11.005
Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.
M. Snuderl (2011)
10.1038/nrg2843
The widespread regulation of microRNA biogenesis, function and decay
J. Krol (2010)
10.1371/JOURNAL.PBIO.0020363
Human MicroRNA Targets
B. John (2004)
10.1016/0092-8674(93)90586-F
Cell
AC Tose (1993)



This paper is referenced by
Epigenetic therapy a good BET for glioblastoma? A systems biology approach to identify a rational combination therapy.
Olga Gusyatiner (2018)
10.1186/s12935-017-0458-y
Integrated genomic characterization of cancer genes in glioma
A. Liang (2017)
10.4155/fmc.14.106
Cancer stem cells as a target population for drug discovery.
C. Bouvard (2014)
10.1093/jnen/nly022
Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas
S. Ferguson (2018)
10.1016/j.bbrc.2016.10.064
Anthelmintic drug ivermectin inhibits angiogenesis, growth and survival of glioblastoma through inducing mitochondrial dysfunction and oxidative stress.
Y. Liu (2016)
10.4103/2152-7806.189296
Traumatic brain injury and subsequent glioblastoma development: Review of the literature and case reports
V. Tyagi (2016)
10.18632/oncotarget.12550
Correction: From the core to beyond the margin: a genomic picture of glioblastoma intratumor heterogeneity
Marc Aubry (2016)
The identification of microRNAs to predict glioma prognosis
Josie L Hayes (2015)
10.1101/156646
Distinct epigenetic shift in a subset of Glioma CpG island methylator phenotype (G-CIMP) during tumor recurrence
C. F. de Souza (2017)
GO-PCA : An Unsupervised Method to Explore Gene Expression Data Using Prior
FlorianWagner (2015)
10.7287/peerj.preprints.1780v1
OncoLnc: Linking TCGA survival data to mRNAs, miRNAs, and lncRNAs
Jordan Anaya (2016)
10.1155/2014/146170
MicroRNA as New Tools for Prostate Cancer Risk Assessment and Therapeutic Intervention: Results from Clinical Data Set and Patients' Samples
A. Cannistraci (2014)
10.1093/bioinformatics/btv298
Interactive analysis of large cancer copy number studies with Copy Number Explorer
S. Newman (2015)
Biomarqueurs prédictifs de l'activité du bevacizumab chez des patients porteurs de gliomes de haut grade à la récidive
E. Tabouret (2015)
10.1007/s11060-014-1520-4
The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma
S. Kizilbash (2014)
10.1038/srep46575
Oncogenic activity of SOX1 in glioblastoma
I. Garcia (2017)
10.5772/INTECHOPEN.76873
Receptor Tyrosine Kinase Interaction with the Tumor Microenvironment in Malignant Progression of Human Glioblastoma
Yujiao Gong (2018)
10.1186/s40425-019-0763-1
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
M. Najjar (2019)
10.18632/oncotarget.20560
TERT promoter status and gene copy number gains: effect on TERT expression and association with prognosis in breast cancer
M. Gay-Bellile (2017)
10.1007/s11060-017-2458-0
Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations
C. Kunos (2017)
10.1038/onc.2017.145
CECR1-mediated cross talk between macrophages and vascular mural cells promotes neovascularization in malignant glioma
C. Zhu (2017)
10.1016/j.molcel.2015.09.002
EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling.
F. Liu (2015)
10.18632/aging.102526
Genomic landscapes by multiregion sequencing combined with circulation tumor DNA detection contribute to molecular diagnosis in glioblastomas
Chao Yang (2019)
Pre-treatment neutrophils count as a prognostic marker to predict chemotherapeutic response and survival outcomes in glioma: a single-center analysis of 288 cases.
Z. Wang (2020)
10.17116/neiro202084031113
[Theranostics for glioblastoma with monoclonal antibodies to the epidermal growth factor receptor].
A. Kopylov (2020)
10.1055/s-0039-1688911
Glioblastoma Multiforme and Genetic Mutations: The Issue Is Not Over Yet. An Overview of the Current Literature.
N. Montemurro (2019)
10.1101/834531
NF1 regulates mesenchymal glioblastoma plasticity and aggressiveness through the AP-1 transcription factor FOSL1
C. Marques (2019)
10.1096/fj.201901075R
Estrogen‐related receptor β activation and isoform shifting by cdc2‐like kinase inhibition restricts migration and intracranial tumor growth in glioblastoma
D. Tiek (2019)
10.21037/TCR.2017.03.32
Molecular characterization of short-term primary cultures and comparison with corresponding tumor tissue of Brazilian glioblastoma patients
A. Cruvinel-Carloni (2017)
10.1634/theoncologist.2018-0845
Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers.
J. Subramanian (2019)
10.1007/s13402-019-00463-x
QKI deficiency maintains glioma stem cell stemness by activating the SHH/GLI1 signaling pathway
B. Han (2019)
10.1084/jem.20172170
PIP4K2A as a negative regulator of PI3K in PTEN-deficient glioblastoma
Y. J. Shin (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar